Curious about Chemours (CC) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Chemours (CC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.
Analysts Estimate Chemours (CC) to Report a Decline in Earnings: What to Look Out for
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CC to Sell Former Titanium Dioxide Taiwan Site Land for $360M
CC agrees to sell its former Taiwan titanium dioxide site land for about $360M, aiming to cut debt as part of its portfolio and balance-sheet optimization.
Chemours: Solid Momentum Despite One-Time Costs In Q3
Chemours remains challenged by weak end markets, but progress on environmental liabilities and Opteon growth support medium-term prospects. Q3 results were mixed, with disruptions impacting earnings, but the resolution of outages and Opteon gains in the TSS segment provide optimism for improvement. TT segment struggles with weak construction activity, but price increases and supply rationalization should help results bottom in 6–9 months.
Chemours Q3 Earnings Lag Estimates Amid Operational Disruptions
CC posts a Q3 profit rebound with $60M in net income, driven by strong Thermal & Specialized Solutions amid mixed segment results.
The Chemours Company (CC) Q3 2025 Earnings Call Transcript
The Chemours Company ( CC ) Q3 2025 Earnings Call November 7, 2025 8:00 AM EST Company Participants Brandon Ontjes - Vice President of Investor Relations Denise Dignam - President, CEO & Director Shane Hostetter - Senior VP & CFO Conference Call Participants John McNulty - BMO Capital Markets Equity Research Peter Osterland - Truist Securities, Inc., Research Division John Ezekiel Roberts - Mizuho Securities USA LLC, Research Division Arun Viswanathan - RBC Capital Markets, Research Division Joshua Spector - UBS Investment Bank, Research Division Patrick Fischer - Goldman Sachs Group, Inc., Research Division Hassan Ahmed - Alembic Global Advisors Laurence Alexander - Jefferies LLC, Research Division Jeffrey Zekauskas - JPMorgan Chase & Co, Research Division Vincent Andrews - Morgan Stanley, Research Division Roger Spitz - BofA Securities, Research Division Aaron Rosenthal - JPMorgan Chase & Co, Research Division Presentation Operator Good morning. My name is Gigi, and I'll be your conference operator today.
Chemours (CC) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Chemours (CC) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Earnings Preview: Chemours (CC) Q3 Earnings Expected to Decline
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemours: Getting In Before The Upside And Before Q3
Chemours Company (CC) remains a speculative 'Buy' ahead of Q3. CC offers significant upside potential, driven by Opteon growth, market recovery, and the recent settlement of major legacy liabilities. Despite elevated leverage and earnings volatility, I see no immediate financial distress and expect improving fundamentals through 2027E.
3 Industrial Stocks Ready to Benefit From Fed Cuts and Spending
Price action is one of the most important metrics to watch out for when deciding whether a potential investment setup is bullish or bearish. However, despite its importance, price action is only half the picture because relying solely on it without linking to fundamental reasons risks capital blindly.
Chemours Enters Strategic Agreement With SRF to Boost Supply
CC partners with SRF to expand global supply chain, boost operational flexibility and strengthen its high-value product mix.
Chemours Q2 Earnings & Revenues Beat Estimates on Higher Volumes
CC posts Q2 earnings and sales beat driven by volume and pricing gains, but issues softer sequential guidance.
